Ken Griffin Phio Pharmaceuticals Corp. Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.73 - $1.1 $21,240 - $32,006	-29,097 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$0.99 - $1.99 $1,929 - $3,878	1,949 Added 7.18%	29,097 $29,000
Q3 2021 Nov 15, 2021	SELL	$1.62 - $2.28 $16,031 - $22,562	-9,896 Reduced 26.71%	27,148 $55,000
Q2 2021 Aug 16, 2021	BUY	$1.87 - $2.8 $25,940 - $38,841	13,872 Added 59.87%	37,044 $83,000
Q1 2021 May 17, 2021	BUY	$2.48 - $4.05 $57,466 - $93,846	23,172 New	23,172 $62,000
Q4 2020 Feb 16, 2021	SELL	$2.01 - $3.32 $24,477 - $40,430	-12,178 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$1.95 - $2.94 $23,747 - $35,803	12,178 New	12,178 $26,000

Ticker PHIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,658,700
Market Cap $32.8M
Description
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.